🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
PharmaBlock Sciences (Nanjing), Inc. (SHE:300725)
China flag China · Delayed Price · Currency is CNY
36.85
-2.01 (-5.17%)
Nov 20, 2026, 3:04 PM CST

SHE:300725 Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Operating Revenue
2,1831,9681,6861,7251,5941,201
Other Revenue
6.576.573.090.450.490.36
2,1901,9741,6891,7251,5951,202
Revenue Growth
10.60%16.93%-2.12%8.18%32.71%17.55%
Cost of Revenue
1,5131,3971,1061,018878.71632.85
Gross Profit
676.83577.86582.74707.2715.99568.78
Selling, General & Admin
285.36242.56238.47253.44248.49174.63
Research & Development
125.3108.72107.33169.17168.32114.02
Other Operating Expenses
14.7311.486.7314.811.898.28
Operating Expenses
456.39382.4356.43447.24435.78299.34
Operating Income
220.44195.46226.31259.95280.21269.44
Interest Expense
--34.22-60.91-66.1-45.72-9.18
Interest & Investment Income
38.1743.1345.7624.7926.7249.42
Currency Exchange Gain (Loss)
-4.12-4.1223.650.4634.45-16.92
Other Non Operating Income (Expenses)
-39.48-0.51-2.964.58-0.9213.47
EBT Excluding Unusual Items
215.01199.74231.86223.69294.72506.23
Impairment of Goodwill
---0.44---
Gain (Loss) on Sale of Investments
5.290.689.36-21.331.991.67
Gain (Loss) on Sale of Assets
0.451.15-0.42-0.04
Asset Writedown
21.21-2.47-0.96-14.8-4.38-0.17
Other Unusual Items
8.528.529.0933.430.94-
Pretax Income
250.49207.61248.9221.38323.26507.77
Income Tax Expense
28.9223.8729.3624.01-2.634
Earnings From Continuing Operations
221.56183.74219.54197.36325.89503.77
Minority Interest in Earnings
---0-11.67-17.21
Net Income
221.56183.74219.54197.36314.22486.56
Net Income to Common
221.56183.74219.54197.36314.22486.56
Net Income Growth
10.15%-16.31%11.24%-37.19%-35.42%164.14%
Shares Outstanding (Basic)
233209200199199198
Shares Outstanding (Diluted)
233209200201200199
Shares Change
15.53%4.61%-0.90%0.62%0.37%6.09%
EPS (Basic)
0.950.881.100.991.582.46
EPS (Diluted)
0.950.881.100.981.572.44
EPS Growth
-4.66%-20.00%12.25%-37.58%-35.66%148.98%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Jan '23 Dec '21
Free Cash Flow
-0.65527.23184.7-68.93-311.3-267.73
Free Cash Flow Per Share
-0.002.520.93-0.34-1.55-1.34
Dividend Per Share
0.3800.2800.2800.3100.1000.100
Dividend Growth
35.71%0%-9.68%210.00%0%30.04%
Gross Margin
30.91%29.27%34.51%40.99%44.90%47.33%
Operating Margin
10.07%9.90%13.40%15.07%17.57%22.42%
Profit Margin
10.12%9.31%13.00%11.44%19.70%40.49%
Free Cash Flow Margin
-0.03%26.70%10.94%-4.00%-19.52%-22.28%
EBITDA
358.21330.24357.09374.25366.45322.64
EBITDA Margin
16.36%16.73%21.15%21.69%22.98%26.85%
D&A For EBITDA
137.77134.78130.78114.386.2453.2
EBIT
220.44195.46226.31259.95280.21269.44
EBIT Margin
10.07%9.90%13.40%15.07%17.57%22.42%
Effective Tax Rate
11.55%11.50%11.79%10.85%-0.79%
Revenue as Reported
2,1901,9741,6891,7251,5951,202
Advertising Expenses
-2.551.441.930.930.6